LLY

903.03

-0.91%↓

JNJ

234.74

-0.53%↓

ABBV

204.61

-0.07%↓

NVS

148.59

+0.32%↑

AZN

185.89

+0.76%↑

LLY

903.03

-0.91%↓

JNJ

234.74

-0.53%↓

ABBV

204.61

-0.07%↓

NVS

148.59

+0.32%↑

AZN

185.89

+0.76%↑

LLY

903.03

-0.91%↓

JNJ

234.74

-0.53%↓

ABBV

204.61

-0.07%↓

NVS

148.59

+0.32%↑

AZN

185.89

+0.76%↑

LLY

903.03

-0.91%↓

JNJ

234.74

-0.53%↓

ABBV

204.61

-0.07%↓

NVS

148.59

+0.32%↑

AZN

185.89

+0.76%↑

LLY

903.03

-0.91%↓

JNJ

234.74

-0.53%↓

ABBV

204.61

-0.07%↓

NVS

148.59

+0.32%↑

AZN

185.89

+0.76%↑

Inicio・Lista de Acciones・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Abierto

1.28 -1.54

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.25

Máximo

1.3

Métricas clave
By Trading Economics
Ingresos	2.7M -24M
BPA	-0.354
Empleados	171
EBITDA	-5.3M -28M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+106.98% upside

Dividendos
By Dow Jones
Próximas Ganancias	7 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-615K 80M
Apertura anterior	2.82
Cierre anterior	1.28

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.43 / 1.6 Soporte y Resistencia

Pliant Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

23 mar 2026, 23:47 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mar 2026, 22:55 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mar 2026, 21:51 UTC

Adquisiciones, fusiones, absorciones

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mar 2026, 23:59 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

23 mar 2026, 23:59 UTC

Charlas de Mercado

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mar 2026, 23:50 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mar 2026, 23:37 UTC

Charlas de Mercado

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mar 2026, 22:42 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Global Equities Roundup: Market Talk

23 mar 2026, 22:42 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mar 2026, 22:40 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mar 2026, 22:23 UTC

Charlas de Mercado

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mar 2026, 22:22 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mar 2026, 22:21 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mar 2026, 22:21 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mar 2026, 22:20 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mar 2026, 22:20 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mar 2026, 22:19 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mar 2026, 22:19 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mar 2026, 22:18 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mar 2026, 22:15 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mar 2026, 22:08 UTC

Charlas de Mercado

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mar 2026, 21:42 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

23 mar 2026, 21:42 UTC

Charlas de Mercado

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mar 2026, 21:32 UTC

Ganancias

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mar 2026, 21:32 UTC

Ganancias

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mar 2026, 21:32 UTC

Ganancias

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mar 2026, 21:10 UTC

Noticias de Eventos Importantes

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mar 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

23 mar 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

23 mar 2026, 20:50 UTC

Charlas de Mercado

Ganancias

Noticias de Eventos Importantes

Basic Materials Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Pliant Therapeutics Inc previsión

Precio Objetivo

By TipRanks

106.98% repunte

Estimación a 12 Meses

Media 2.67 USD 106.98%

Máximo 3 USD

Mínimo 2 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.43 / 1.6Soporte y Resistencia

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.